Björklund Pharma focuses on the development of innovative biopharmaceutical products, with a primary focus on thymosin beta-4 (Tβ4). The company prioritizes ensuring safety, optimizing bioavailability, and providing scientific documentation to support the therapeutic potential and regulatory compliance of Tβ4-based treatments.